Related by context. Frequent words. (Click for all words.) 73 hematological 64 evaluable patients 62 evaluable 61 hematologic malignancies 59 dose limiting toxicities 59 tumor regression 59 myelofibrosis 58 febrile neutropenia 58 hematological malignancies 58 malignancies 58 cutaneous T cell 57 chemotherapy regimens 57 antitumor activity 57 eculizumab 57 pathologic 56 toxicities 56 dasatinib 56 lymphomas 56 tumor shrinkage 56 histologic 56 cell lymphomas 56 chronic myeloid leukemia CML 56 chronic lymphocytic leukemia CLL 55 rituximab 55 follicular lymphoma 55 TREANDA 55 unresectable 55 immune mediated 54 imatinib 54 HGS ETR1 54 solid tumors 54 hematopoietic 54 neurotoxicity 54 monotherapy 54 mg BID 54 myelodysplastic syndromes MDS 54 FOLFOX 54 ACTEMRA 54 bortezomib 54 prognostic factors 54 sarcomas 54 lupus nephritis 54 clinically meaningful 54 acute myeloid leukemia AML 54 composite endpoint 54 NSCLC 53 mitoxantrone 53 systemic lupus erythematosus SLE 53 brain metastases 53 VIDAZA 53 pharmacodynamic 53 fluorouracil 53 soft tissue sarcomas 53 immunologic 53 mg/m2 53 CYT# 52 glioblastoma 52 INCB# [002] 52 adalimumab 52 diabetic nephropathy 52 carcinomas 52 myelodysplastic syndromes 52 neoplasms 52 clinically relevant 52 plus ribavirin 52 metastatic melanoma 52 Perifosine 52 AP# [003] 52 invasive bladder 52 tolerability 51 topotecan 51 tumor progression 51 cutaneous 51 anthracycline 51 leukemias 51 infliximab 51 vandetanib 51 HRPC 51 renal cell carcinoma 51 Phase 2a trial 51 gemcitabine 51 epratuzumab 51 etanercept 51 liver metastases 51 sunitinib 51 Xcytrin 51 DMARDs 51 IMGN# 51 clofarabine 51 peripheral neuropathy 51 FOLOTYN 50 cyclophosphamide 50 Pixantrone 50 hepatocellular carcinoma 50 MGCD# [001] 50 cytotoxicity 50 VELCADE 50 secondary endpoints 50 Secondary endpoints included 50 Marqibo 50 docetaxel